In a feasibility study, anti-CEA CAR T cell therapy resulted in significant respiratory toxicities in patients with advanced CEACAM5+ gastrointestinal malignancies, including pancreatic cancer. The gene discussed is CEACAM5; the disease is pancreatic neoplasm.